Skip to content
AnalystLens

BridgeBio Pharma 8-K Report, Rights Modification (Jun 23, 2025)

Reports
Shareholder Matters·Corporate Changes·Exhibits & Filings
Filing Date
Filed June 23, 2025
Period End
June 20, 2025
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Oct ’21Oct ’21
  3. Material agreement8-K · Sep ’23Sep ’23
  4. Material agreement8-K · Aug ’26Aug ’26

Summary

Summary of the 8-K filed June 23, 2025. Cited figures are marked; the original filing is the authoritative source.

BridgeBio Pharma, Inc. reported in this Form 8-K that its stockholders approved several proposals at the June 20, 2025 Annual Meeting of Stockholders.

The most significant governance change is an amendment to the Amended and Restated Certificate of Incorporation that limits the liability of certain officers as permitted under current Delaware law. The amendment was previously approved by the Board, became effective upon filing with the Delaware Secretary of State on June 23, 2025, and is filed as Exhibit 3.1. At the meeting, 173,876,974 of the 189,868,970 shares of common stock entitled to vote were present or represented by proxy.

Stockholders elected five Class III directors, Neil Kumar, Ph.D., Charles Homcy, M.D., Douglas A. Dachille, Ronald J. Daniels and Andrew W.

Lo, Ph.D., to serve until the 2028 Annual Meeting. They also approved, on a non-binding advisory basis, the compensation of the named executive officers, ratified Deloitte & Touche LLP as the independent registered public accounting firm for fiscal 2025, and approved an amendment and restatement of the 2021 Amended and Restated Stock Option and Incentive Plan that increases the shares reserved for issuance by 5,000,000. For investors, the filing's key items are the officer exculpation amendment, the expanded equity plan share reserve, and the advisory say-on-pay vote.

The say-on-pay proposal received 117,646,141 votes for and 37,945,949 votes against, with 1,231,991 abstentions and 17,052,893 broker non-votes. The filing does not discuss business operations, financial results or other strategic developments.

Key Highlights

  1. Officer exculpation amendment: Stockholders approved an amendment to limit the liability of certain officers as permitted under Delaware law. It became effective June 23, 2025, upon filing with the Delaware Secretary of State (Exhibit 3.1).
  2. Equity plan expansion: Stockholders approved the amendment and restatement of the 2021 Amended and Restated Stock Option and Incentive Plan, which increases the reserved shares by 5,000,000 (Exhibit 10.1). Votes were 128,958,695 for and 26,656,756 against.
  3. Board election: Five Class III directors were elected to serve until the 2028 Annual Meeting. Neil Kumar, Ph.D. received 154,328,316 votes for, and Andrew W. Lo, Ph.D. received 126,242,281 votes for, with 30,581,800 withheld.
  4. Say-on-pay vote: The non-binding advisory vote on named executive officer compensation was approved, with 117,646,141 votes for, 37,945,949 against and 1,231,991 abstentions.
  5. Auditor ratification: Stockholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 173,767,607 votes for, 56,401 against and 52,966 abstentions.
  6. Officer exculpation vote count: The officer exculpation proposal passed with 151,194,026 votes for, 5,574,758 against and 55,297 abstentions.
  7. Quorum and participation: 173,876,974 of 189,868,970 eligible shares were present or represented by proxy at the Annual Meeting.

Frequently Asked Questions

  1. What does the officer exculpation amendment do?

    It amends the Amended and Restated Certificate of Incorporation to limit the personal liability of certain officers of the Company, as permitted under current Delaware law. The Board approved the amendment subject to stockholder approval, and it became effective upon filing with the Delaware Secretary of State on June 23, 2025.

  2. How much additional equity capacity did stockholders approve?

    Stockholders approved an amendment and restatement of the 2021 Amended and Restated Stock Option and Incentive Plan that, among other things, increases the number of shares of common stock reserved for issuance by 5,000,000 shares. The plan text in the form approved is filed as Exhibit 10.1.

  3. Did stockholders support the executive compensation program?

    The non-binding advisory vote on named executive officer compensation was approved. The filing reports 117,646,141 votes for, 37,945,949 votes against, 1,231,991 abstentions and 17,052,893 broker non-votes.

  4. Who was elected to the Board, and for what term?

    Neil Kumar, Ph.D., Charles Homcy, M.D., Douglas A. Dachille, Ronald J. Daniels and Andrew W. Lo, Ph.D. were elected as Class III directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are duly elected and qualified. Withheld votes ranged from 2,495,765 for Dr. Kumar to 30,581,800 for Dr. Lo.

  5. Which independent auditor was ratified for 2025?

    Stockholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The proposal received 173,767,607 votes for, 56,401 against and 52,966 abstentions, with no broker non-votes.